Evidence of Lentinan based on clinical study

Biotherapy

Volumn 20, Issue 4, 2006, Pages 403-409

  Yoshino, Shigefumi ^a   Hazama, Syoichi ^a   Kawaoka, Toru ^a   Kondo, Hiroshi ^a   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Evidence; Lentinan; QOL; Survival benefit

Indexed keywords

DOXORUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; LENTINAN; MITOMYCIN C; TEGAFUR;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; STOMACH CANCER;

EID: 33748626548     PISSN: 09142223     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Chihara, G., Maeda, Y.Y., Hamuro, J., et al.: Inhibition of mouse sarcoma 180 by polysaccharides from lentinans edodes (Berk.) Sing. Nature 222: 687-688, 1969.
2. Maeda, Y. Y. and Chihara, G.: The effect of neonatal thymectomy on the antitumor activity of lentinan, carboxymethylpachymaran and zymosan, and their effects on various immune responses. Int. J. Cancer 11: 153-161, 1973.
3. Hamuro, J. and Chihara, G.: Lentinan, a T-cell-oriented immunopotentiator. Its experimental and clinical applications and possible mechanism of immune modulation. In Immunomodulation agents and their mechanism (edited by Fenichel, R. L. and Chirigos, M.A.), Marcel Dekker Inc., New York and Basel, 1984, pp. 409-435.
4. Oka, M., Hazama, H., Suzuki, M., et al.: In vitro and in vivo analysis of human leukocytes binding by the antitumor polysaccharide, lentinan. Int. J. Immunopharmac. 18: 211-216, 1996.
5. Lentinan: Lentinan J. Toxicol. Sci. 5(suppl.): 59-72, 1980.
6. Hamuro, J., Rollinghoff, M. and Wagner, H.: β (1-3) glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res. 38: 3080-3085, 1978.
7. Hamuro, J., Rollinghoff, M. and Wagner, H.: Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the β (1-3) glucan type lentinan and its analogues. Immunology 39: 551-559, 1980.
8. BIOTHERAPY 4: 941-948, 1990.
9. BIOTHERAPY 5: 721-733, 1991.
10. Ochiai, T., Isono, K., Suzuki, T., et al.: Effect of immunotherapy with Lentinan on patients' survival and immunological parameters in patients with advanced gastric cancer: Results of a multi-central randomized controlled study. Int. J. Immunotherapy: 161-169, 1992.
11. BIOTHERAPY 7: 1224-1233, 1993.
12. Biotherapy 10: 60-65, 1996.
13. Nakano, H., Namatame, K., Nemoto, H., et al.: A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quolity of life. Hepatogastroenterology 46: 2662-2668, 1999.
14. Biotherapy 19 (Suppl. I): 61, 2005.